Preterm birth<unk> s have been shown to reduce the occurrence and mortality of infant respiratory distress syndrome, a life-threatening condition caused by underdeveloped lungs. Current evidence suggests that giving<unk>  corticosteroids reduces risk of late miscarriages and baby deaths. The baby is also less likely to develop respiratory distress syndrome or die during or after birth. They are also less likely to have intraventricular hemorrhage (bleeding of the brain), necrotizing enterocolitis (problems with the bowels), or systemic infections (infections affecting the whole body) in the first two days of life.<unk> s do not appear to increase the number of women who develop infection of the fetal membranes (chorioamnionitis) or of the womb (endometritis). There is robust evidence that a single course of<unk>  corticosteroids (i.e., 24 mg of betamethasone or dexamethasone), when there is a risk of preterm birth (at less than 34 weeks of gestation), reduces the risk of child death, regardless of resource level. Multiple gestation Further research must be conducted to adequately determine outcomes of<unk>  administration for multiple pregnancies. However, certain national clinical practice guidelines recommend the usage of<unk> s for preterm birth regardless of multiple gestation. Preterm premature rupture of membranes<unk> s have also been shown to have definite beneficial effect in treating the condition of preterm premature rupture of membranes (PPROM). Similar to its effects on preterm birth, research evidence suggests that the administration of<unk> s to patients with PPROM reduces risks of neonatal mortality, intraventricular hemorrhage and respiratory distress syndrome.
Antenatal steroid
Neonatal resuscitation
Infant massage
Cordotomy
Surfactant therapy
Parenteral nutrition
Precipitate delivery
Assisted feeding